May 13, 2024
“Auna S.A. (AUNA)… Cepeda’s views back up his Overweight (Buy) rating on the stock, and his $14 price-target points toward a robust 110% upside potential for the next 12 months. (To watch Cepeda’s track record, click here)… Contineum Therapeutics (CTNM)… Hung goes… Continue Reading…
Recent Comments